Commentary|Videos|November 20, 2026

Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond

Pharmacists can assess tolerability and identify OTC or compounded products patients may be taking alongside therapy, according to Biykem Bozkurt, MD, PhD.

In an interview with Pharmacy Times, Biykem Bozkurt, MD, PhD, professor of medicine and senior dean at Baylor College of Medicine and principal investigator of the SYNCHRONIZE-CVOT trial, discussed where survodutide might fit alongside current incretin therapies for patients with obesity and cardiovascular risk. The discussion centered around new data from SYNCHRONIZE-CVOT (NCT06077864), the phase 3 cardiovascular outcomes trial of survodutide presented at the American Heart Association Scientific Sessions 2026.

Key Takeaways

  • Bozkurt framed survodutide as a separate class whose glucagon component may add complementary effects on liver metabolism and visceral fat.
  • She positioned survodutide as an alternative for patients with obesity and established cardiovascular disease or risk.
  • Ongoing studies, including LIVERAGE, will define survodutide's role in liver disease, and the agent remains investigational.

Bozkurt described survodutide as a different class that combines glucagon and glucagon-like peptide-1 receptor agonism. She said it has potential complementary effects on liver metabolism and cardiometabolic markers, as seen in SYNCHRONIZE-CVOT and in the treatment of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, and visceral adiposity.

For individuals at risk for cardio-kidney-liver-metabolic disorder and for those with established cardiovascular disease or cardiovascular risk, she called survodutide a good alternative to existing products for addressing both cardiovascular risk and metabolic risk factors. Those risk factors include visceral adiposity, abnormal lipid profiles, abnormal blood pressure, and liver fibrosis and fat deposition.

Bozkurt placed survodutide within what she called a comprehensive cardiometabolic, liver, and kidney platform and summarized the evidence across the SYNCHRONIZE program: cardiovascular safety in SYNCHRONIZE-CVOT, effective weight loss in SYNCHRONIZE-1 (NCT06066515), and glycemic control in patients with diabetes in SYNCHRONIZE-2 (NCT06066528). Ongoing studies, including LIVERAGE (NCT06632444), will address survodutide's role and efficacy in individuals with liver disease.

For pharmacists, her comments frame survodutide's potential role around the breadth of cardiometabolic risk it may address rather than weight loss alone, particularly for patients whose obesity overlaps with liver disease, dyslipidemia, or hypertension. Survodutide remains investigational and has not been approved by the FDA.


Related to this article